The FDA has publicly criticized Aventis, the manufacturer of the antibiotic Ketek for not taking action about safety reports it had concerning the risk of serious liver damage. The critical letter was posted on the FDA website. Ketek was approved for use in 2004. The doctor who signed up the most patients for clinical trials plead guilty to fraud. Ketek’s problems come in the midst of an increasing awareness of how drug companies sometimes hide unfavorable data from consumers and health officials in order to increase profits.